martes, 17 de noviembre de 2026

Unexpected approach could crack key cancer signaling pathway Cancer researchers have attempted to target the WNT pathway for decades without success due to severe toxicity issues. A new paper could solve that problem. Written byAllison Whitten, PhD

Unexpected approach could crack key cancer signaling pathway Cancer researchers have attempted to target the WNT pathway for decades without success due to severe toxicity issues. A new paper could solve that problem. Written byAllison Whitten, PhD https://www.drugdiscoverynews.com/unexpected-approach-could-crack-key-cancer-signaling-pathway-17660 For decades, targeting the WNT signaling pathway in cancer has eluded drug developers. That’s because while it’s a crucial pathway that drives uncontrolled cell division and tumor growth, it’s also essential in maintaining homeostasis in normal healthy tissues. Thus, any therapeutic that targets WNT and harms cancer cells also harms healthy cells, leading to severe toxicity and intolerable side effects in preclinical models. For example, a common strategy has been to target a pair of enzymes that regulate the WNT pathway, TNKS1 and TNKS2. But earlier work with dual inhibitors led to gastrointestinal damage in animal models. Now, Lukas Dow’s lab at Weill Cornell Medicine may have found a surprising way around these harsh side effects. His lab first built genetic tools to silence TNKS1 and TNKS2 independently of each other rather than silencing both. “When we started using them in cancer cell lines we noticed something unexpected: In some cases, suppressing TNKS2 alone was sufficient to suppress WNT,” Dow told DDN.

No hay comentarios:

Publicar un comentario